Aethlon Medical, Inc. is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. The company is headquartered in San Diego, California and currently employs 9 full-time employees. The firm is focused on advancing the Hemopurifier (HP), a clinical-stage immunotherapeutic device intended for applications in cancer, life-threatening viral infections, and organ transplantation and other areas of significant unmet needs. In pre-clinical studies, the Hemopurifier has exhibited the capacity to remove harmful extracellular vesicles (EVs) and enveloped viruses from biological fluids, utilizing its proprietary lectin-based mechanism. These extracellular vesicles have been implicated in disease processes such as immune suppression and metastasis in cancer as well as in the progression of severe life-threatening infectious diseases. The United States Food and Drug Administration (FDA) has designated the Hemopurifier as a Breakthrough Device for the treatment of individuals with advanced or metastatic cancer who are unresponsive to or intolerant of standard of care therapy.
최신 재무제표(Form-10K)에 따르면, Aethlon Medical Inc의 총 자산은 $0이며, 순손실입니다.
AEMD의 주요 재무 비율은 무엇인가요?
Aethlon Medical Inc의 유동비율은 0이고, 순이익률은 0, 주당 매출은 $0입니다.
Aethlon Medical Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Aethlon Medical Inc 주요 수익원은 Retail Consumer Banking이며, 최신 수익 발표에서 수익은 303,160,000입니다. 지역별로는 United States이 Aethlon Medical Inc의 주요 시장이며, 수익은 303,160,000입니다.